

Disorders of the Nervous System

Protein Profiling of RGS6, a Pleiotropic Gene Implicated in Numerous Neuropsychiatric Disorders, Reveals Multi-Isoformic Expression and a Novel Brain-Specific Isoform

K. E. Ahlers-Dannen,* J. Yang,* M. M. Spicer, B. Maity, A. Stewart, J. G. Koland, and R. A. Fisher

<https://doi.org/10.1523/ENEURO.0379-21.2021>

Department of Neuroscience and Pharmacology, The Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242

Abstract

A metanalysis identified regulator of G-protein signaling 6 (*RGS6*) as one of 23 loci with pleiotropic effects on four or more human psychiatric disorders. This finding is significant as it confirms/extends the findings of numerous other studies implicating *RGS6* in CNS function and pathology. *RGS6* is a highly conserved member of the RGS protein family whose cellular roles are likely affected by mRNA splicing and alternative domain inclusion/exclusion. Indeed, we previously identified multiple *RGS6* splice variants predicted to produce 36 distinct protein isoforms containing either long (*RGS6L*) or short (*RGS6S*) N-terminal domains, an incomplete or intact GGL domain, and nine alternative C termini. Unfortunately, sequence similarities between the isoforms have made it difficult to confirm their individual existence and/or to determine their unique functions. Here, we developed three *RGS6*-specific antibodies that recognize all *RGS6* protein isoforms (*RGS6-fl*), the N-terminus of *RGS6L* isoforms (*RGS6-L*), and an 18-amino acid alternate C-terminal sequence (*RGS6-18*). Using these antibodies, we demonstrate that *RGS6L*(+GGL) isoforms, predominating in both mouse (both sexes) CNS and peripheral tissues, are most highly expressed in the CNS. We further identify three novel *RGS6* protein bands that are larger (61, 65, and 69-kDa) than the ubiquitously expressed 53- to 57-kDa *RGS6L*(+GGL) proteins. Importantly, we show that the 69-kDa protein is a brain-specific dephospho form of the 65-kDa band, the first identified phosphorylated *RGS6* isoform. Together, these data begin to define the functional significance behind the complexity of *RGS6* gene processing and further clarifies *RGS6*'s physiological roles by resolving tissue-specific *RGS6* protein expression.

Key words: expression; isoforms; neuropsychiatric; pleiotropic; *RGS6*; splicing

Significance Statement

Psychiatric disorders are highly associated with polygenic variation. Consistent with this, a SNP (single nucleotide polymorphism) (rs2332700) in regulator of G-protein signaling 6 (*RGS6*) is linked to autism spectrum disorder, bipolar disorder, major depression, and schizophrenia. *RGS6* is a highly conserved gene whose complex alternative mRNA splicing produces numerous protein isoforms with high sequence similarity, hindering their functional characterization. Therefore, while aberrant *RGS6* signaling and/or expression have been linked to various neuropsychiatric disorders, it is unclear which isoforms are important. This study functionally delineates between the various *RGS6* isoforms within mouse. We demonstrate that *RGS6* is most highly expressed in CNS, characterize the predominant isoforms, and identify a brain-specific *RGS6* protein highly expressed in brain regions associated with various psychiatric disorders.

Introduction

Psychiatric disorders are a leading cause of worldwide disability and affect >25% of the population (Kessler and Wang, 2008; GBD 2016 Disease and Injury Incidence and Prevalence Collaborators, 2017). Research in this area has noted that risk is highly associated with polygenic variation (Sullivan et al., 2018; Smoller et al., 2019). Furthermore, it is now clear that psychiatric disorders are not distinct and there is significant genetic overlap between them (Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013; Anttila et al., 2018). Highlighting this point, a recent meta-analysis conducted by the Cross-Disorder Group of the Psychiatric Genomic Consortium (Cross-Disorder Group of the Psychiatric Genomics Consortium, 2019) of 232,964 psychiatric patients and 494,162 controls revealed 23 genetic loci with significant pleiotropic effects on $\geq 4/8$ disorders studied: anorexia nervosa, attention deficit hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, and Tourette syndrome.

One of the 23 pleiotropic genetic loci described was a SNP (rs2332700) in regulator of G-protein signaling 6 (RGS6), previously identified in a GWAS of schizophrenic patients (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014), that was linked not only to schizophrenia, but also to autism spectrum disorder, bipolar disorder, and major depression. This finding is significant because of the study's magnitude and as it confirms/extends the findings of other human and animal studies implicating RGS6 in CNS function and pathology (Fig. 1). In particular, alterations in RGS6 signaling and/or expression have been associated with: alcohol use disorders (rs11621871; Stewart et al., 2015; Chen et al., 2017), anxiety/depression (Stewart et al., 2014), Parkinson's disease (Bifsha et al., 2014; Luo et al., 2019; Petyuk et al., 2021), Alzheimer's disease (rs4899412; Moon et al., 2015), motor coordination (Maity et al., 2012), adult hippocampal neurogenesis (Gao et al., 2020), as well as human cataracts, mental retardation, and microcephaly (c. 1369–1 G > C; Chograni et al., 2014).

Received September 17, 2021; accepted November 24, 2021; First published December 8, 2021.

The authors declare no competing financial interests.

Author contributions: K.E.A.-D., J.Y., and R.A.F. designed research; K.E.A.-D., J.Y., M.M.S., B.M., A.S., J.G.K., and R.A.F. performed research; K.E.A.-D., J.Y., and R.A.F. contributed unpublished reagents/analytic tools; K.E.A.-D., J.Y., M.M.S., and R.A.F. analyzed data; K.E.A.-D., J.Y., and R.A.F. wrote the paper.

This work was supported by National Institutes of Health Grants CA161882 and AA025919 and MJ Fox Grant 11551.

*K.E.A.-D. and J.Y. are co-first authors.

B. Maity's present address: Center of Biomedical Research Lucknow, Uttar Pradesh 226014, India.

A. Stewart's present address: Department of Pharmacology, Florida Atlantic University, Boca Raton, FL 33431.

Correspondence should be addressed to R. A. Fisher at rory-fisher@uiowa.edu.

<https://doi.org/10.1523/ENEURO.0379-21.2021>

Copyright © 2022 Ahlers-Dannen et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

RGS proteins modulate the magnitude and duration of G protein-coupled receptor (GPCR) signaling by facilitating heterotrimeric G-protein inactivation, a function bestowed by their RGS domain. RGS6 is a highly conserved (Fig. 2) member of the R7 subfamily, which modulates $G\alpha_{i/o}$ signaling and is distinguished by two additional domains, DEP and GGL, responsible for both membrane targeting and protein stability (Ross and Wilkie, 2000; Hooks et al., 2003). RGS6's cellular roles may also be affected by mRNA splicing and alternative domain inclusion/exclusion. Indeed, multiple RGS6 splice variants have been identified which are predicted to produce 36 distinct RGS6 protein isoforms containing either long (RGS6L) or short (RGS6S) N-terminal domains, an incomplete or intact GGL domain (–/+GGL), and nine alternative C-termini (Fig. 3; Chatterjee et al., 2003). Unfortunately, because of sequence similarity it has been difficult to confirm the existence of many of these isoforms or to determine their function. Therefore, while aberrant RGS6 signaling and/or expression have been linked to various neuropsychiatric disorders, it is unclear which RGS6 isoforms are important.

Adding further complexity are studies demonstrating RGS6 has critical physiological and pathophysiological functions outside the CNS as well. In the periphery RGS6 has been shown to: act as a critical tumor suppressor (Berman et al., 2004; Huang et al., 2011; Dai et al., 2011; Maity et al., 2011, 2013; Jiang et al., 2014; Luo et al., 2015; Yang et al., 2016), negatively modulate parasympathetic heart regulation (Posokhova et al., 2010; Yang et al., 2010; Wydeven et al., 2014), promote cardiovascular development (Chakravarti et al., 2017), associate with adiposity (Sibbel et al., 2011), and mediate heart-ischemic injury (Rorabaugh et al., 2017), doxorubicin-induced cardiac toxicity (Huang et al., 2011; Yang et al., 2013), as well as alcohol-induced cardiac, hepatic, and gastrointestinal damage (Stewart et al., 2015; Fig. 1). Interestingly, not all of these peripheral functions (i.e., tumor suppression) rely on RGS6's ability to negatively regulate $G\alpha_{i/o}$ (Maity et al., 2011).

As the list of RGS6's critical physiological and pathophysiological roles continues to grow, particularly with regards to neuropsychiatric disorders, it is imperative to perform a comprehensive analysis of RGS6 isoform expression. We hypothesize such an analysis will help to clarify the functional significance behind the complexity of RGS6 gene processing.

Materials and Methods

Mice

We have previously described the generation of and genotyping methods for RGS6^{–/–} mice (Yang et al., 2010). For these studies, RGS6^{–/–} mice were backcrossed onto the C57BL6 background for five generations. Three-month-old male and female RGS6^{+/+} and RGS6^{–/–} mice were used for the experiments described in the manuscript. All animal procedures described were approved by the University of Iowa Institute for Animal Care and Use Committee.




Figure 1. RGS6 has numerous neuropsychiatric, physiological, and pathophysiological roles. This diagram highlights the many neuropsychiatric, physiological, and pathophysiological functions that have been attributed to RGS6 as well as the primary literature describing these functions.

RGS6L α 1(+GGL) conservation map

NCBI's predicted protein sequence for human RGS6L α 1 (+GGL) (isoform 1-NP_001191245.1), the largest RGS6 isoform identified by Chatterjee et al. (2003) was BLASTED against the following taxids: *Gorilla*, *Macaca*, *Papio*, *Soricidae*, *Mus*, *Oryctolagus*, *Sus*, *Camelus*, *Delphinus*, *Orcinus*, *Bos bovis*, *Ovis*, *Equus*, *Felis*, *Canis canis*, *Ailuropoda*, *Vulpes*, *Chiroptera*, *Loxodonta*, *Trichechus*, *Dasypodidae*, and *Didelphimorphia* using NCBI's default settings. The sequence IDs with the highest amino acid conservation were placed in the MegAlign program (part of the DNASTAR Lasergene 12 Core Suit) and aligned using the Clustal W Method. This alignment was used to generate a circular map using the DNASTAR GenVision program.

RGS6 structure homology modeling

A structural model of RGS6L α 1(+GGL) based on the RGS9/G β ₅ complex structure (2PBI; Cheever et al., 2008) was created using the Swiss-PdbViewer (Swiss Institute of Bioinformatics). Domains within the predicted RGS6L α 1 (+GGL) amino acid sequence that did not align with the RGS9/G β ₅ complex were modeled with an in-house algorithm (clean.swiss.pl) created by the Elcock lab (University of Iowa), which implements the Loopy program (Xiang et al., 2002). The model was visualized with VMD (Theoretical and Computational Biophysics Group, Beckman Institute, University of Illinois at Urbana-Champaign).

Cell culture and transfection for protein half-life assays

HEK293T cells were plated in 12-well plates at 3.5×10^5 cells/well and were cultured in high-glucose DMEM (Sigma-Aldrich) supplemented with 10% fetal bovine serum (Invitrogen 26140), 100 units/ml penicillin (Invitrogen 15140), and 100 μ g/ml streptomycin (Invitrogen 15140); 24 h later, cells were transiently co-transfected using the Lipofectamine 2000 system (ThermoFisher Scientific 116680) with a pcDNA3.1-HA vector containing G β ₅ (G β ₅-HA; gifted by Songhai Chen), a pEGFP vector containing R7BP (R7BP-GFP; gifted by Martemyanov, Scripps, FL), and a pcDNA3.1 vector containing RGS6 (1:1:2 ratio, total DNA = 1 μ g/well). Transfection media was exchanged for new supplemented DMEM media at 6 h following transfection; 24 h posttransfection, supplemented DMEM was removed, and cells were cultured in serum free supplemented DMEM containing 100 μ M cycloheximide (Sigma C6255) for 0, 2, 4, 6, 12, and 24 h.

Antibody generation

Three different polyclonal RGS6 antibodies were used in this study. Antibodies to the N-terminal domain of RGS6L (RGS6-L) were generated with a synthetic peptide immunogen corresponding to residues 1–19 (MAQGSG DQRAVGVADPEESC-COOH) of RGS6L (Biosynthesis Inc; Chatterjee et al., 2003). Antibodies to the unique splice




Figure 2. The RGS6 protein sequence is highly conserved across the animal kingdom. This figure shows a conservation map of the largest RGS6 isoform we previously identified (Chatterjee et al., 2003) in different mammalian species. This isoform is designated RGS6L α 1(+GGL) as it includes the extended N-terminus found in RGS6 long (RGS6L) isoforms, the GGL domain, as well as the alternative α 1 C-terminal sequence encoded by exons 18 and α . Each column within the conservation map represents a single amino acid and conservation of color within a column represents amino acid conservation. When looking at the histogram around the outside of the conservation map, green represents 100% amino acid conservation whereas gray represents <100% conservation.

forms of RGS6 that retain exon 18 sequences (RGS6-18) were generated (Biosynthesis Inc.) with a peptide immunogen corresponding to 14 amino acids in this region (–CKPESEQRRRTSLEK; Chatterjee et al., 2003). Antibodies to full length RGS6L (RGS6-fl) were generated (Elmira Biologicals) to recombinant RGS6L following its expression, solubilization, and purification from inclusion bodies in bacteria.

Western blotting

Cell culture

Media was aspirated off cells and 100 μ l of ice cold RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, and 50 mM

Tris-HCl; pH 8) containing protease (Roche 11836170001) and phosphatase (Sigma p5726) inhibitors was added to each well. Cells and RIPA were then placed in prechilled tubes, vortexed for 30 s, incubated on ice for 5 min, and centrifuged at 8000 rpm (4°C) for 10 min. Supernatant was transferred to tubes containing 4 \times SDS PAGE sample buffer and boiled for 5 min before loading onto gels.

Tissues

Tissues were prepared for Western blot analysis as previously described (Yang et al., 2016).

Western blots were probed with home-made rabbit anti-RGS6-specific antibodies (RGS6-L, RGS6-18, and RGS6-fl; 1:1000–2000), rabbit anti-G β 5 (a gift from William F Simonds, 1:1000 dilution; Zhang et al., 1996),




Figure 3. Predicted protein structure and binding partners for human RGS6 protein isoforms. RGS6 is a member of the R7 subfamily (RGSs 6, 7, 9, 11) distinguished by two additional domains, DEP and GGL, which target these proteins to the membrane (through interaction with R9AP and/or R7BP) and promote their stability (through interaction with Gβ₅), respectively. In addition to DEP-mediated and GGL-mediated spatial function and regulation, RGS6’s cellular roles are also likely affected by mRNA splicing and alternative domain inclusion/exclusion. **A**, Illustration of the 36 RGS6 protein isoforms encoded by RGS6 mRNA splice variants we identified (Chatterjee et al., 2003). RGS6 proteins possess either long (RGS6L) or short (RGS6S) N-terminal domains, an incomplete or intact GGL domain, and nine alternative C-terminal sequences. **B**, Sequence alignment of the N-terminal region of RGS6 to that of RGS7, RGS9, and RGS11. The gray box represents a region of low sequence conservation that was used to develop the RGS6L antibody, RGS6-L. **C**, The protein sequence of an alternatively spliced region of RGS6 present in the C terminus of 56% of RGS6 protein isoforms that was used to develop RGS6-18 antibody. The approximate location at which the RGS6-L and RGS6-18 antibodies bind to RGS6 proteins is denoted in **A** by an antibody icon.

rabbit anti-RGS7 (a gift from Vladlen Z. Slepak, 1:1000 dilution; Levay et al., 1999), rabbit anti-RGS9-2 (a gift from Steve Gold, 1:1000 dilution; Psifogeorgou et al., 2007; Psifogeorgou et al., 2011), mouse-anti-RGS11 (a gift from Jason Chen, 1:1000 dilution; Chen et al., 2010), as well as commercial mouse monoclonal anti-α-tubulin (Calbiochem, CP06-100UG, 1:5000 dilution) and rabbit anti-actin (Sigma A2066, 1:1000), primary antibodies. LICOR Odyssey goat anti-mouse (926-32220 and 926-32210) and goat anti-rabbit (926-32211 and 926-68071) secondary antibodies were used at a 1:10,000 dilution for protein visualization with the Odyssey system.

Immunohistochemistry

Mice were perfused with a saline solution at a rate of 1 ml/min for 5 min, followed by infusion of a freshly made fixative solution (4% paraformaldehyde, 23 mM NaH₂PO₄, and 77 mM Na₂HPO₄) at a rate of 1 ml/min for 15 min. Tissues were collected and soaked in the fixative solution (4% paraformaldehyde, 23 mM NaH₂PO₄, and 77 mM Na₂HPO₄) overnight. After fixation, tissues were embedded in paraffin and sectioned. Tissue sections of RGS6^{+/+} and RGS6^{-/-} mice were processed to examine expression of RGS6 as we described previously (Maity et al., 2011). Briefly, sections were dewaxed in xylene, treated with a graded series of alcohol

solutions, immersed in 3% hydrogen peroxide to block endogenous peroxidase activity, blocked with 5% bovine serum albumin and then incubated overnight at 4°C with rabbit anti-RGS6-fl antibody. Following washing (3 × 10 min) in PBS, sections were incubated for 1 h at room temperature with peroxidase-conjugated secondary antibodies (Cell Signaling, 7074). A positive reaction was detected by exposure to stable diamin-obenzidene (General Biosciences Corporation) for 3 min. The sections were counterstained in Harris hematoxylin and observed under the microscope. This is true for all tissues samples except heart. For mice hearts, frozen sections were blocked for 1 h at 4°C in blocking buffer, containing 10% goat serum, 0.3% Triton X-100, 80.4 mM Na₂HPO₄, 19.0 mM NaH₂PO₄, pH7.4, and then incubated overnight at 4°C with rabbit anti-RGS6-fl antibody. Following washing (3 × 10 min) in the blocking butter, sections were incubated for 1 h at room temperature with Alexa-conjugated secondary antibodies (Fisher Scientific, A11011).

Bioinformatic prediction of RGS6 phosphorylation sites

Putative phosphorylation sites in RGS6Lα1(+GGL) were identified using the Group-based Prediction System (GPS) 3.0 from Cuckoo Workgroup. This software uses hierarchical grouping of protein kinases to identify possible

kinase-specific or family-specific phosphorylation sites in each protein sequence based on a metric measuring similarity of the protein sequence to known phosphorylation site motifs. The software considers each specific serine/threonine/tyrosine residue and 7 amino acids up and downstream of that residue in generating a prediction score, a measure of the likelihood of peptide phosphorylation. In our analysis, the threshold was set to high and predicted site/kinases were considered if their GPS prediction score was at least 1 above the cutoff value defined by the software ($\Delta\text{Score} \geq 1$). Phosphorylation sites and corresponding kinases meeting these criteria are listed in Extended Data Figure 7-1. Subsequently, a diagram depicting each putative RGS6 phosphorylation site and the corresponding kinase with the highest prediction score was constructed (Fig. 7A).

Phosphatase/kinase assays

Analysis of RGS6 phosphorylation and de-phosphorylation was assayed in RGS6^{+/+} and RGS6^{-/-} whole-brain tissue lysates. Tissues were homogenized in the absence of phosphatase inhibitor cocktail. Lysates were diluted to a final concentration of 2 $\mu\text{g}/\mu\text{l}$ in 1 \times NEBuffer Pack for Protein MetalloPhosphatases (New England BioLabs). A total of 100 units λ phosphatase (New England BioLabs) were added to each reaction as indicated. For kinase assays, lysates were supplemented with 2 mM ATP and 1 mM MgCl₂ required for enzyme activity, and with or without activators of PKA, PKC, or Ca²⁺-stimulated kinases as shown in Figure 7D; 30 mM NaF was added to reactions lacking λ phosphatase and in kinase reactions to inhibit endogenous phosphatases. Reactions were incubated at 30°C for 20 min and terminated through the addition of 1 \times sample buffer. Samples were subjected to SDS-PAGE and immunoblotting as described above.

Experimental design and statistical analysis

All graphical data are expressed as mean \pm SEM. All sample sizes reported are based on conservative power analyses estimating $\beta = 0.2$ (80%) with statistical significance being evaluated against $\alpha = 0.05$. Effect sizes were estimated using Cohen's *d* formulation before calculating power analyses. Significant differences within tissue expression data (Figs. 5B, 8A, 9A; Extended Data Figs. 5-1, 8-1, and 9-1) were analyzed via two-way ANOVA with Fisher's LSD *post hoc* adjustment. Significant differences within immunoreactivity data (Fig. 7C,E) were also analyzed via two-way ANOVA with Fisher's LSD *post hoc* adjustment. All data were analyzed using XLSTAT software.

Results

Development and characterization of RGS6 antibodies confirms *in vivo* expression of RGS6L(+GGL) and identifies novel RGS6 protein bands

We previously cloned 36 distinct RGS6 mRNA splice forms, from a human brain cDNA library, which were predicted to produce long (RGS6L) and short (RGS6S) RGS6 protein isoforms with an incomplete or intact GGL domain (-/+GGL) and nine alternative C-termini (Fig. 3A;

Chatterjee et al., 2003). In this study, we endeavored to confirm the existence of these RGS6 isoforms *in vivo*. Therefore, we developed three antibodies, against: the whole RGS6L protein (RGS6-fl), the N-terminus of RGS6L protein isoforms (RGS6-L), and an alternative 18-amino acid sequence found in the C-terminus of 56% of RGS6 isoforms (RGS6-18). Figure 3B shows the N-terminal sequence of RGS6 to which the RGS6-L antibody was generated and the lack of sequence conservation in this region with other R7 subfamily members. Figure 3C shows the alternatively spliced 18-amino acid sequence to which the RGS6-18 antibody was generated. Because the RGS6-fl antibody was generated to recombinant RGS6L α 2(+GGL) this antibody likely targets multiple epitopes on RGS6 proteins. All antibodies were generated in rabbit against the human protein or its sequences that are conserved in mouse. We examined the ability of these three antibodies to detect native RGS6 protein isoforms by comparing Western blots of whole-brain lysates derived from RGS6^{+/+} [wild-type (WT)] to RGS6^{-/-} [knock-out (KO)] mice (Yang et al., 2010) to identify RGS6-specific bands. Figure 4A shows representative Western blots from our studies.

Anti RGS6-fl recognizes three RGS6-specific bands identified by the magenta, blue and green arrows (Fig. 4A, left panel). The most abundant of these immunoreactive bands (magenta arrow) has a molecular weight of 53–57 kDa, a size range corresponding to RGS6L protein isoforms containing the GGL domain, required for protein stabilization (RGS6L(+GGL); Extended Data Fig. 4-1; Chen et al., 2003; Cheever et al., 2008; Chatterjee et al., 2003). In addition, RGS6-fl recognizes 61-kDa (blue arrow) and 69-kDa (green arrow) bands that are larger than previously described RGS6 isoforms. We show below that the 69-kDa isoform represents a novel brain-specific form of RGS6L (Fig. 5). Finally, the RGS6-fl antibody also detected a 58-kDa band (Fig. 4A, asterisk) in both RGS6^{+/+} and RGS6^{-/-} brain lysates, demonstrating this is not a RGS6 protein isoform. We confirmed by immunoblotting using an RGS7 antibody that this band represents RGS7 (data not shown), the R7 subfamily member most closely related to RGS6. This was unsurprising given that RGS6-fl was generated to recombinant RGS6L.

Interestingly, while protein bands corresponding to RGS6L(+GGL) were readily apparent when using the RGS6-fl antibody isoforms lacking the GGL domain (RGS6L(-GGL), 49–52 kDa; Extended Data Fig. 4-1) were not (Fig. 4A, left panel) even with long blot exposures (data not shown). Because the RGS6-fl antibody can detect RGS6L(-GGL) isoforms expressed in HEK 293 cells (Fig. 4B), the apparent absence of these isoforms *in vivo* is likely because of their relative instability compared with RGS6L(+GGL) isoforms, as suggested by cycloheximide chase experiments in HEK cells (Fig. 4C,D), and/or low abundance when compared with RGS6L(+GGL) isoforms. Interestingly, the RGS6-fl antibody also did not detect RGS6S(+/-GGL) proteins (34–41 kDa; Extended Data Fig. 4-1) in mouse brain (Fig. 4A, left panel), although RGS6S transcripts were originally cloned from a human brain cDNA library (Chatterjee et al., 2003). As




Figure 4. RGS6 antibodies confirm *in vivo* RGS6L(+GGL) expression and identify novel RGS6 protein bands. **A**, Western blots of whole-brain lysates derived from RGS6^{+/+} (WT) and RGS6^{-/-} (KO) mice using antibodies against: the whole RGS6L protein (RGS6-fl, left panel), the N-terminus of RGS6L protein isoforms (RGS6-L, middle panel), and an 18-amino acid sequence found in 56% of RGS6 protein isoforms (RGS6-18, right panel). Magenta arrows represent RGS6 protein bands corresponding in size to RGS6L(+GGL) isoforms; (Extended Data Fig. 4-1)). Blue and green arrows represent RGS6 protein bands that are larger (61- and 69-kDa) than the predicted sizes (≤ 57 kDa) of the RGS6 species we previously identified (Chatterjee et al., 2003). Asterisks represents the RGS7 protein band which is non-specifically recognized by the RGS6-fl and RGS6-18 antibodies. **B**, Western blot analysis demonstrating that while the RGS6-fl antibody recognizes both RGS6L and RGS6S isoforms overexpressed in HEK cells, the RGS6-L antibody specifically recognizes the RGS6L isoforms. Yellow arrows represent additional RGS6 protein bands produced by overexpression of the RGS6L (+/-GGL) and RGS6S (+/-GGL) vector constructs. These bands are smaller than the predicted sizes for the RGS6L (+/-GGL) and RGS6S (+/-GGL) isoforms and likely represent additional protein isoforms produced by novel translation start sites encoded by all constructs (Extended Data Fig. 4-2). **C**, Representative Western blots from cycloheximide chase experiments characterizing the differential stability of the RGS6L (+/-GGL) and RGS6S (+/-GGL) protein isoforms over a 24 h period. Yellow arrows represent the additional low molecular weight RGS6 protein bands recognized by the RGS6-fl antibody in panel **B**. These bands were not included in the final analysis. **D**, Densitometric analysis of protein degradation comparing the four RGS6 protein isoforms ($N = 3$) in **C**.

with the RGS6L(-GGL) isoforms, the inability to detect the RGS6S isoforms is not because of a lack of antibody specificity because anti-RGS6-fl readily detects RGS6S(+/-GGL) proteins following expression in HEK293 cells (Fig. 4B). Therefore, lack of RGS6S isoforms *in vivo* may be due once again to their relative instability, suggested by cycloheximide chase experiments (Fig. 4C,D), and/or low their abundance when compared with RGS6L isoforms.

As the RGS6-fl antibody recognized not only RGS6, but also RGS7, a second antibody, RGS6-L, was generated against the first 19 amino acids (MAQGSGDQRAVGVD PEES) of the RGS6L isoforms, a sequence that shows minimal conservation across the R7 subfamily (Fig. 3B). The caveat to the RGS6-L antibody is that it does not detect RGS6S(+/-GGL) isoforms (Fig. 4B) which have a truncated N-terminus (Fig. 3A). However, given that the RGS6-fl antibody did not detect endogenous RGS6S




Figure 5. Tissue expression profiling of RGS6 in 31 mouse tissues using the RGS6-L antibody. Using purified RGS6-L antibody we conducted an analysis of RGS6L expression in 31 tissues throughout the mouse body. **A**, Representative Western blots demonstrating that, in RGS6^{+/+} (WT) and RGS6^{+/-} (H) mice compared with RGS6^{-/-} (KO) mice, many CNS and peripheral tissues express the 53- to 57-kDa RGS6L(+GGL) protein isoforms (magenta arrow) identified previously (Chatterjee et al., 2003). The blue and green arrows indicate the novel 61- and 69-kDa RGS6 protein bands identified in Figure 4A, and the orange arrow indicates a third novel 65-kDa band identified in the larger expression profile. While the 65- and 69-kDa RGS6 protein bands were brain-specific, the 61-kDa band was identified in multiple tissues. Note: this figure was constructed from multiple gels. Therefore, we have placed vertical black lines between tissue samples to denote RGS6 expression levels cannot be directly compared between tissues. **B**, Densitometric quantitative analysis of the 53- to 57-kDa RGS6L(+GGL) isoforms (**A**, magenta arrow) reveal that they are significantly expressed in CNS tissues as well as peripherally in atrium and bladder. Two-way ANOVA found significant effects of strain ($F_{(2,258)} = 143.75, p \leq 0.0001$), tissue ($F_{(30,258)} = 44.11, p \leq 0.0001$), and their interaction ($F_{(59,258)} = 15.93, p \leq 0.0001$). Data were analyzed via two-way ANOVA with Fisher's LSD *post hoc* adjustment. Data are presented as mean \pm SEM; * $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$, **** $p \leq 0.0001$ ($N = 3-8$ RGS6^{+/+} mice, 2-6 RGS6^{+/-} mice, and 2-8 RGS6^{-/-} mice). Extended Data Figure 5-1 compares significant differences in RGS6 expression across tissues in RGS6^{+/+} mice. Extended Data Figure 5-2 shows the conservation of an RGS6 SNP in primates. CTX = cerebral cortex, OFB = olfactory bulb, MB = midbrain, CB = cerebellum, SC = spinal cord, Ret = retina, WAT = white adipose tissue, BAT = brown adipose tissue, Ofat = Omental fat, Spl = spleen, Thy = thymus, Pros = prostate, Test = testis, Brst = breast, Ov = ovary, Ut = uterus, Atr = atrium, Vent = ventricle, Dia = diaphragm, Sk mus = skeletal muscle, Eso = esophagus, Stom = stomach, S int = small intestine, L int = large intestine, Panc = pancreas, Kid = kidney, Ad gl = adrenal gland, Blad = bladder, Plat = platelet.

isoforms in mouse brain (Fig. 4A, left panel), or in any other mouse peripheral tissues tested (data not shown), use of the RGS6-L antibody was deemed an acceptable alternative strategy. Subsequent Western

blot validation of the RGS6-L antibody revealed that it detects the same three RGS6 protein bands (magenta, green, and blue arrows) as theRGS6-fl antibody, but, unlike the RGS6-fl antibody, it does not detect RGS7

(Fig. 4A, middle panel, asterisk). Again, the most abundant immunoreactive band detected with both RGS6L and RGS6-fl antibodies is the 53- to 57-kDa band (magenta arrow), corresponding to RGS6L (+GGL) isoforms (Extended Data Fig. 4-1), followed by the brain-specific 69-kDa band (green arrow) and then the 61-kDa band (Fig. 4A, left and middle panels, blue arrow). No other RGS6 proteins are detected by these two antibodies.

While the RGS6-L antibody eliminates detection of RGS7, it does not allow for easy delineation between the nine RGS6L(+GGL) isoforms, as they fall within a narrow molecular weight range (53–57 kDa; Extended Data Fig. 4-1). Therefore, a third antibody, RGS6-18, was generated against the alternative PESEQRRRTSLEKFTRSV amino acid sequence (Fig. 3C) encoded by exon 18 present near the C-terminus of 56% of RGS6 isoforms (Fig. 3A, dark gray box starting at amino acid 456). As the RGS6-L and RGS6-18 antibodies were both made in rabbit, it was not possible to directly compare their banding pattern in a single blot. However, Western blot analysis using RGS6-18 shows strong immunoreactivity of the 69-kDa brain-specific band (green arrow) and the 53- to 57-kDa band (magenta arrow) corresponding to RGS6L (+GGL) isoforms (Fig. 4A, right panel). The RGS6-18 antibody also recognizes RGS7 (Fig. 4A, right panel, asterisk) as a portion of the alternative amino acid sequence (RRTSLEKFTRSV) is present ($\leq 75\%$ conservation) in a subset of RGS7 isoforms.

In summary, Western blot analysis of RGS6 isoform expression in mouse brain tissue reveals that two of the antibodies, RGS6-fl and RGS6-18, also detect RGS6's closest evolutionary relative, RGS7. However, the RGS6-L antibody generated against the N-terminal sequence unique to RGS6L isoforms eliminates this problem. Further analysis revealed that while RGS6 proteins with molecular weights corresponding to RGS6L(+GGL) isoforms were readily detectable, RGS6L(-GGL) and RGS6S(+/-GGL) isoforms were not, possibly because of their relative instability or low abundance.

There are two remaining points of interest that arose from these initial cell culture and mouse tissue experiments. First, we discovered that overexpression of RGS6L(+/-GGL) and RGS6S(+/-GGL) transcripts in culture results in the expression of several protein bands, detected by the RGS6-fl antibody, that are not only equivalent in size but also smaller than the predicted protein molecular weights (Fig. 4B, yellow arrows, C). Subsequent analysis of both transcript sequence and protein band molecular weights suggest that the small bands are likely RGS6 protein isoforms produced through alternative start sites. These alternative start sites are present in all four overexpressed transcripts, and thus similar low molecular weight bands are produced by each. As these alternative start sites exist in exons 8 and 10 (Extended Data Fig. 4-2, yellow stars), present in all RGS6L and RGS6S transcripts, we would predict that these low molecular weight RGS6 proteins may be expressed in any tissue expressing RGS6. Second, Western blots of mouse whole-brain lysate

revealed at least two additional RGS6 protein bands that were larger (61- and 69-kDa, blue and green arrows, respectively) than all previously described isoforms (Fig. 4A, left and middle panels). Both protein bands were detected by the RGS6-fl and RGS6-L antibodies, but only the 69-kDa protein band was detected by the RGS6-18 antibody (Fig. 4A, right panel). From these data, the significance of these bands was uncertain. They are bona fide RGS6 protein isoforms as they were not detected in RGS6^{-/-} mice, but whether they represent novel RGS6 isoforms or posttranslational modified proteins remained unclear.

RGS6L(+GGL) is most highly expressed in CNS but is also expressed in several peripheral tissues

As the RGS6-L antibody does not recognize RGS7, we used it to conduct a comprehensive Western blot analysis of RGS6L expression in 31 tissues throughout the mouse body (Fig. 5). To standardize the Westerns and allow for quantitative analysis of RGS6 expression across tissues, one RGS6^{+/+} whole-brain lysate was included as a control/constant denominator in every blot. These blots, and the subsequent densitometric analysis, revealed that RGS6L is significantly expressed in all CNS tissues analyzed, including, but not limited to the: cerebral cortex, olfactory bulb, midbrain, cerebellum, spinal cord, and retina (Fig. 5). Furthermore, RGS6L isoforms were also found at significant, albeit lower levels (Fig. 5; Extended Data Fig. 5-1) in two peripheral mouse tissues (heart and bladder). Finally, while statistical significance was not achieved because of small sample size, tissue variability, or low level of expression, RGS6 protein bands were also identified in lung, kidney, prostate, heart, omental fat, stomach, intestines, and breast (Fig. 5). This RGS6 expression profile corresponds well with previous reports describing the physiological and pathophysiological roles of RGS6 (Fig. 1).

To compliment this broad expression profile, we conducted an immunohistochemical analysis of RGS6 distribution (Fig. 6) in tissues found to express RGS6 protein bands via Western blot (Fig. 5). The RGS6-fl antibody was used for this analysis, instead of the RGS6-L antibody, as it proved to stain tissues more reliably (data not shown). Furthermore, simultaneous staining of both RGS6^{-/-} and RGS6^{+/+} tissues demonstrated that, unlike with Western blotting, the RGS6-fl antibody does not detect RGS7 proteins in intact tissues (Fig. 6). In the CNS, this analysis revealed that RGS6 is expressed ubiquitously across the cortical layers and confirmed what we had previously reported in the cerebellum (Maity et al., 2012), that RGS6 is expressed predominantly by neurons in the granule cell layer and Purkinje neurons. Likewise, there is a predominant neuronal expression of RGS6 in the spinal cord and olfactory bulb, as well as the midbrain, the latter finding confirming our previous evidence that RGS6 is expressed in midbrain dopaminergic neurons (Bifsha et al., 2014; Luo et al., 2019). Finally, in the retina, RGS6 proteins are highly expressed in ganglion cells as well as retinal pigmented epithelium and to a lesser extent in bipolar cells, rods, and cones. Moving to the periphery, robust RGS6




Figure 6. Immunohistochemical analysis of RGS6 tissue distribution. Representative images from an immunohistochemical analysis of RGS6 protein distribution, using the RGS6-fl antibody, in mouse RGS6^{+/+} (WT) CNS (left panel) and peripheral (right panel) tissues shown to express RGS6 protein bands via Western (Fig. 5A). Complimentary tissues collected from RGS6^{-/-} (KO) controls confirmed that the RGS6-fl antibody, while it recognizes RGS7 via Western blots (Fig. 4A), is specific for RGS6 in tissue sections.

expression is detected throughout the walls of the heart, in omental fat cell plasma, and in epithelial cells of lung, bladder, breast, intestines, stomach, and kidney. A lower RGS6 expression is also seen in connective/muscular tissues adjacent to epithelial cells (Fig. 6).

Finally, an in-depth analysis of the RGS6 expression profile blots also elucidated the most prevalent RGS6L isoforms. Consistent with what had been seen earlier in whole-brain lysates, the molecular weight of the protein bands observed suggested that RGS6L(+GGL) isoforms predominate (magenta arrow, 53 to 57-kDa) in all tissues examined. Furthermore, it became apparent that, in

addition to the large 61- and 69-kDa bands (blue and green arrows, respectively), the RGS6-L antibody also detected a third novel protein band of ~65-kDa (orange arrow) in RGS6^{+/+} and RGS6^{+/-}, but not RGS6^{-/-}, mice. This band, while faint, was clearly visible in most CNS tissues blots with longer exposure times. Examination of the expression profile for all three bands revealed that while the 61-kDa band is expressed in multiple tissues (brain, omental fat, breast, heart, stomach, intestine, lung, and bladder) the 65- and 69-kDa bands are brain-specific (Fig. 5). Once again, the significance of these findings, whether these bands represented novel isoforms or

posttranslationally modified proteins, remained unclear. However, considering RGS6's association with various neuropsychiatric disorders, we were very intrigued by the discovery that two of these novel RGS6 protein bands were brain-specific.

The novel, 65-kDa brain-specific RGS6 is a phosphorylated protein

Phosphorylation is a common form of posttranslational modification. Indeed, the R7 family members, RGS7 and RGS9, have previously been shown to be phosphorylated (Benzing et al., 1999, 2002; Balasubramanian et al., 2001; Sokal et al., 2003; Garzón et al., 2005; Ibi et al., 2011). There is also evidence from large-scale proteomic screens of the murine brain that supports the existence of RGS6 phospho-peptides with modifications on S244, S437, S459, and S490 of RGS6L α 1 (Huttlin et al., 2010; Safaei et al., 2011; Trinidad et al., 2012). Furthermore, group-based prediction of protein phosphorylation using GPS 3.0 software indicates that there are potentially 46 threonine, serine, and tyrosine residues in the RGS6L α 1 (+GGL) protein that can serve as kinase substrates (Fig. 7A; Extended Data Fig. 7-1). Several of these residues were also identified as sites of potential phosphorylation via a second, similar program, PhosphoNET, as well (Extended Data Fig. 7-1). Therefore, we hypothesized that the large novel RGS6L protein bands may represent phospho-proteins and subsequently performed an *in vitro* phosphatase assay using protein lysates prepared from the whole RGS6^{+/+} and RGS6^{-/-} mouse brains. This assay revealed that addition of λ phosphatase to the lysate mixture eliminated the 65-kDa RGS6L protein band, but not the 61- and 69-kDa RGS6L species (Fig. 7B). This assay suggests that the 65-kDa RGS6L protein band (orange arrow) represents a brain-specific phospho-protein.

Additional experiments revealed that the 65- and 69-kDa RGS6 isoforms represent interconvertible phospho and dephospho forms of RGS6, respectively. First, in support of this, analysis of the effects of phosphatase treatment on RGS6 isoforms revealed that phosphatase-induced loss of the 65-kDa band was accompanied by an increase in the 69-kDa band (Fig. 7C). This suggested that dephosphorylation of the 65-kDa band did not result in its disappearance, but instead promoted an upward shift in its electrophoretic mobility to 69 kDa. Although phosphorylation does not change the electrophoretic mobility of most proteins, it can lead to an upward or downward shift in mobility depending on the protein. Our results suggested that dephosphorylation of the 65-kDa form produced an upward mobility shift. Noteworthy examples of proteins showing upward mobility shifts on phosphorylation include cyclin-dependent kinase-2 (Cdk-2; Gu et al., 1992), Cdk1 (Larochelle et al., 1998), and Cdk-7 (Garrett et al., 2001). To confirm this, we performed kinase reactions in brain extracts with ATP and various kinase activators. Figure 7D,E show that incubation of extracts with ATP and Ca²⁺ promoted an increase in the 65-kDa RGS6 band and a decrease in the 69-kDa RGS6 band. These findings corroborate our evidence from Figure 7B,C that the 65-kDa band is a phosphorylated form of RGS6 and

that dephosphorylation leads to an upward mobility shift to the 69-kDa band.

The predicted size of the largest RGS6 isoform shown in Figure 7A is 56.5-kDa (Extended Data Fig. 4-1). Our studies shown in Figure 7B-E show that the 53- to 57-kDa and the 61-kDa isoforms are not affected by phosphatase treatment or by incubation with ATP and kinase activators. Yet, all known members of the RGS6 protein family have some or all of the sequence elements shown in Figure 7A. It is possible that the expected additional protein sequence in the novel brain-specific 69-kDa possesses the site for Ca²⁺-dependent phosphorylation. Alternatively, it may possess sequence elements that confer substrate availability of sequences present in all/most RGS proteins shown in Figure 7A. It is also possible that the 53- to 57-kDa isoforms do not undergo mobility shifts on phosphorylation/dephosphorylation and that the 61-kDa isoform represents a novel RGS6 isoform whose transcript was not identified in the initial cloning effort (Chatterjee et al., 2003).

The novel, 69-kDa brain-specific RGS6 isoform is highly conserved and significantly expressed in all regions of the brain analyzed

We found that the 69-kDa dephospho form of RGS6 was generally easier to detect and quantify in various brain regions than the 65-kDa form, possibly because of dephosphorylation of the 65-kDa isoform following sacrifice and brain dissection. The function of these isoforms in brain is unclear, but a cursory analysis hints at their importance. First, quantification of the 69-kDa band demonstrates that it is significantly expressed, in all RGS6^{+/+} mouse brain tissues assayed (Fig. 8A; Extended Data Fig. 8-1), although its expression level appears to be consistently lower than that of the 53- to 57-kDa RGS6L protein isoforms (Fig. 7B,D). Given its exclusive expression in brain tissue we hereafter refer to the 69-kDa isoform as RGS6B (and the 65-kDa form as p-RGS6B). Second, RGS6B appears to serve an important evolutionary function as Western blot analysis reveals that it is not only expressed in mouse brain tissue but also human brain tissue (Fig. 8B, green arrow).

RGS6 is the only R7 family member expressed in lung, omental fat, bladder, stomach, and intestine

As mentioned earlier, the Western blot profile of RGS6L protein expression (Fig. 5) was consistent with the literature regarding RGS6's physiological and pathophysiological roles (Fig. 1). However, previous analysis of RGS mRNA expression profiles indicate that there is often overlap in the expression of several RGS's within a single tissue. For example, *in situ* hybridization (Gold et al., 1997) and RT-qPCR analyses (Larminie et al., 2004) demonstrated that the entire R7 RGS subfamily is expressed in the brain. Therefore, to determine if, in tissues where it is expressed, RGS6 is the primary R7 subfamily member present we re-probed the RGS6-L Western blots (Fig. 5) with an antibody against G β ₅ (Fig. 9). G β ₅ expression was found to be significantly higher in brain and




Figure 7. Prediction of RGS6 α 1(+GGL) phosphorylation sites and identification of a novel, ~65-kDa brain-specific RGS6 phosphoprotein. **A**, Putative phosphorylation sites within the RGS6 α 1(+GGL) protein were identified using the GPS 3.0 software (Extended Data Fig. 7-1). Sites with the highest prediction score were mapped to the RGS6 α 1(+GGL) protein sequence with the corresponding kinase labeled. Serine residues are indicated in blue, threonine in pink, and tyrosine in green. **B**, A representative Western blot from RGS6^{+/+} (WT) and RGS6^{-/-} (KO) brain tissue lysates treated where indicated with λ phosphatase. The magenta arrow indicates the ~53- to 57-kDa RGS6L (+GGL) isoforms, while the blue, orange, and green arrows indicate the novel RGS6 protein bands (61-, 65-, 69-kDa, respectively) identified in this study. **C**, A densitometric quantification of the 56-, 61-, 65-, and 69-kDa RGS6 protein bands (Column colors correspond to arrow colors in Western, **B**). Two-way ANOVA with Fisher's LSD *post hoc* adjustment revealed a significant effect of λ phosphatase on the expression of the 65-kDa ($p \leq 0.0001$) and 69-kDa ($p \leq 0.0001$) bands relative to their respective untreated samples. Data are presented as

continued

mean \pm SEM; **** p \leq 0.0001 (N = 3 mice per treatment). **D**, A representative Western blot from RGS6^{+/+} (WT) and RGS6^{-/-} (KO) brain tissue lysates treated where indicated with PMA (200 nM), cAMP and Forskolin (10 μ M of each), or Ca²⁺ (10 μ M). **E**, A densitometric quantification of the 56-, 61-, 65-, and 69-kDa RGS6 protein bands (Column colors correspond to arrow colors in Western, **D**). Two-way ANOVA with Fisher's LSD *post hoc* adjustment found a significant effect of Ca²⁺ treatment on the expression of the 65-kDa (p \leq 0.0001) and 69-kDa (p = 0.002) bands relative to their respective untreated samples.

retina versus other tissues (Extended Data Fig. 9-1) as observed for RGS6L (Extended Data Fig. 5-1).

G β ₅ is an atypical G β subunit that forms an obligate dimer with all R7 family members through interaction with their GGL domain (Fig. 3), which is structurally homologous to conventional G γ subunits. Interaction between G β ₅ and R7 family members is obligatory, loss of either interacting partner causes destabilization of the other (Chen et al., 2003). Emphasizing this point, in 2008, Cheever and colleagues solved the crystal structure of RGS9 and showed it in complex with G β ₅ (Cheever et al., 2008). Furthermore, this crystal structure revealed that the interaction between RGS9's GGL domain and G β ₅ mirrors the orientation and interaction of the conventional G β γ dimer. This interaction orientation is believed to be maintained throughout the R7 subfamily, a hypothesis which is supported both by the solving of the crystal structure for RGS7, also in complex with G β ₅ (Patil et al., 2018), but also through structure homology modeling of RGS6L α 2(+GGL) (Fig. 9A, inset). Therefore, loss of G β ₅ expression with RGS6 removal would indicate that RGS6 is the only R7 family member present in that tissue.

These analyses demonstrated that, while most tissues expressing RGS6 also express other R7 family members (G β ₅ expression was maintained after RGS6 loss), there were some tissues, including lung, bladder, stomach, intestine, and omental fat, where RGS6 appeared to be the only R7 family member present (G β ₅ expression was completely lost with loss of RGS6; Fig. 9A). Indeed, Western blot analysis of a subset of the tissues showing a concomitant loss of RGS6 and G β ₅ expression (lung, omental fat, and bladder)

using antibodies against individual R7 family members (RGSs 7, 9-2, and 11) confirmed that RGS6 is the only R7 member expressed there (Fig. 9B).

Discussion

RGS6 pre-mRNA is subject to alternative splicing producing 36 unique transcripts each predicted to produce viable protein isoforms (Chatterjee et al., 2003). Despite knowing about this complex processing, sequence similarities have complicated the study of individual RGS6 isoforms. As such, most research implicating RGS6 in neuropsychiatric disorders or exploring its diverse peripheral roles have taken a global view of its function. This work provides the first comprehensive analysis of RGS6 isoform expression. Using three distinct antibodies generated against the whole RGS6L protein, the N-terminus of RGS6L isoforms, and an alternative amino acid sequence found in the C-terminus of 56% of RGS6 isoforms, we have not only begun to define tissue-specific differences in RGS6 isoform expression but have also identified brain-specific RGS6 protein bands that appear to be phosphorylated/dephosphorylated only in CNS tissues.

RGS6L(+ GGL) isoforms are the most prevalent isoforms expressed *in vivo*

Western blot analyses demonstrate that RGS6L(+ GGL) isoforms predominate throughout the mouse body (Fig. 5, magenta arrow). As the nine possible RGS6L(+ GGL) isoforms fall within a narrow molecular weight range (53–57 kDa; Extended Data Fig. 4-1), we were unable to definitively say which of these isoforms were present.




Figure 8. The 69-kDa brain-specific RGS6 protein band (RGS6B) is highly conserved and significantly expressed in all mouse CNS tissues analyzed. **A**, Densitometric quantification of the 69-kDa, brain-specific RGS6 protein band (Fig. 5A, green arrow) demonstrates that it is significantly expressed in all RGS6^{+/+} (WT) mouse brain tissues, compared with RGS6^{+/-} (H) and RGS6^{-/-} (KO) tissues analyzed. Two-way ANOVA found significant effects of strain ($F_{(2,32)} = 99.51$, p \leq 0.0001), tissue ($F_{(4,32)} = 21.19$, p \leq 0.0001), and their interaction ($F_{(8,32)} = 21.19$, p = 0.000). Data were analyzed via two-way ANOVA with Fisher's LSD *post hoc* adjustment. Data are presented as mean \pm SEM; * p \leq 0.05, ** p \leq 0.01, *** p \leq 0.001, **** p \leq 0.0001 (N = 3–4 RGS6^{+/+} mice, 2–3 RGS6^{+/-} mice, and 3–4 RGS6^{-/-} mice). Extended Data Figure 8-1 compares significant differences in RGS6B expression across tissues in RGS6^{+/+} mice. CTX = cerebral cortex, CB = cerebellum, MB = midbrain, SC = spinal cord, OFB = olfactory bulb. **B**, Western blot analysis of mouse and human brain lysates indicate that the 61- and 69-kDa, brain-specific protein bands (blue and green arrows, respectively) are conserved in mouse and human.




Figure 9. RGS6 is the only R7 family member expressed in bladder, lung, omental fat, stomach, and intestine. **A**, Densitometric quantification of Gβ₅ expression in tissues shown to express RGS6 protein bands via Western (Fig. 5A). Inset, Structure homology modeling of RGS6Lα2(+GGL) in complex with Gβ₅. Two-way ANOVA found significant effects of strain ($F_{(2,135)} = 19.69, p \leq 0.0001$) and tissue ($F_{(15,135)} = 90.64, p \leq 0.0001$). Data were analyzed via two-way ANOVA with Fisher's LSD *post hoc* adjustment. Data are presented as mean \pm SEM; * $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$, **** $p \leq 0.0001$ ($N = 2-6$ RGS6^{+/+} mice, 2-5 RGS6^{+/-} mice, and 3-6 RGS6^{-/-} mice). Extended Data Figure 9-1 compares significant differences in Gβ₅ expression across tissues in RGS6^{+/+} mice. CTX = cerebral cortex, CB = cerebellum, MB = midbrain, SC = spinal cord, OFB = olfactory bulb, Ret = retina, Ofat = Omental fat, Atr = atrium, Vent = ventricle, Brst = breast, Stom = stomach, S int = small intestine, L int = large intestine, Kid = kidney, Blad = bladder. **B**, Representative Western blot analysis of a subset of the tissues from **A** showing a concomitant loss of RGS6 and Gβ₅ expression using antibodies against the individual R7 family members confirmed that RGS6 is the only R7 member expressed there. Note: The Gβ₅ portion of this figure was constructed from multiple blots. Therefore, we have placed vertical black lines between Gβ₅ tissue samples to denote expression levels cannot be directly compared. The first lane labeled WT is a lysate from whole brain for all blots except for the blot for RGS9-2, where it is striatum, as RGS9-2 is not detectable in whole-brain lysates (Luo et al., 2019). WT = RGS6^{+/+}, H = RGS6^{+/-}, and KO = RGS6^{-/-}.

However, using the RGS6-18 antibody, we conclude that, in the brain, at least some of the RGS6L(+GGL) isoforms include the amino acid sequence encoded by exon 18 (Fig. 4A, right panel). Furthermore, we hypothesize that RGS6Lα1(+GGL) and RGS6Lα2(+GGL), which differ only in the inclusion and exclusion, respectively, of the amino acid sequence encoded by exon 18 (Fig. 3), may represent the predominant brain RGS6L(+GGL) isoforms. This hypothesis is supported by the fact that RGS6Lα2(+GGL) (GenBank AF073920) and RGS6Lα1(+GGL) (GenBank AF107619) were the first RGS6L splice forms identified. These results suggest that RGS6Lα1(+GGL) and RGS6Lα2(+GGL) are expressed at relatively high levels compared with other RGS6L(+GGL) transcripts which were not identified until our subsequent cloning study (Snow et al., 1999; Chatterjee et al., 2003).

While the studies above suggest certain RGS6L(+GGL) isoforms may predominate because of relatively high mRNA transcript expression, this is likely not the only explanation for their prevalence. The R7 RGS protein subfamily is distinguished by two unique domains outside of

the RGS domain: the DEP/DHEX domain and the GGL domain. Importantly, the GGL domain is required for interaction with Gβ₅, an atypical Gβ subunit that forms an obligate dimer with all R7 family members, promoting their stability (Chen et al., 2003). Consequently, RGS6L(+GGL) isoforms may be expected to be more stable (Fig. 4D) and thus expressed at higher levels relative to the RGS6L(-GGL) isoforms, which we previously showed do not bind Gβ₅ (Liu and Fisher, 2004).

Interestingly, as with the RGS6L(-GGL) isoforms, we did not identify RGS6 protein bands in the brain corresponding in size to RGS6S isoforms (Fig. 4A; Extended Data Fig. 4-1), despite the fact their corresponding transcripts were originally cloned from a human brain cDNA library (Chatterjee et al., 2003). While this may be explained by low transcript abundance, it may also be caused by protein instability as suggested by our cycloheximide chase experiments (Fig. 4C,D). RGS6L and RGS6S protein isoforms arise via the use of alternative transcription start sites within the RGS6 gene sequence. Specially, while RGS6L protein isoforms are generated using a transcription start site upstream of exon 1 of the RGS6 gene,

RGS6S isoforms arise via a transcription start site within intron 7. Therefore, RGS6S protein isoforms lack the first 140 amino acids present in the N-terminus of RGS6L isoforms, and therefore also lack the DEP/DHEX domain (Fig. 3A). The DEP/DHEX domain is known to promote membrane targeting of R7 family members by facilitating their interaction with two membrane proteins, the retina-specific RGS9 anchor protein (R9AP) and its close relative, R7 family binding protein (R7BP) which is ubiquitously expressed (Fig. 3A; Lishko et al., 2002; Hu and Wensel, 2002; Martemyanov et al., 2003, 2005; Drenan et al., 2005; Anderson et al., 2007; Patil et al., 2018). However, the DEP/DHEX domain may also facilitate the interaction between $G\beta_5$ and R7 family members (Cheever et al., 2008). Recent evidence supports a model whereby R9AP/R7BP strengthens the interaction between the DEP/DHEX and GGL domains with $G\beta_5$ promoting R7 RGS protein stabilization (Masuho et al., 2011; Patil et al., 2018). These findings are consistent with our cycloheximide chase experiments demonstrating that RGS6L isoforms are more stable than RGS6S isoforms (Fig. 4D).

Identification of novel RGS6 protein bands

We identified three RGS6 protein bands that were larger (61-, 65-, and 69-kDa) than any protein isoform predicted from our initial cloning effort (≤ 57 -kDa, Chatterjee et al., 2003). All three bands were RGS6L isoforms as they were recognized by the RGS6-L antibody (Figs. 4A, 5). Of these, the 65- and 69-kDa bands appear to be brain-specific (Fig. 5) phospho (p-RGS6B) and dephospho (RGS6B) forms of RGS6L, respectively. The 65-kDa p-RGS6B band, whose expression is reduced in the presence of λ phosphatase and increased by a Ca^{2+} -stimulated kinase activity, represents the first positively identified RGS6 phospho-protein (Fig. 7B–E). In contrast, the 69-kDa RGS6B protein band is increased by λ phosphatase (Fig. 7B) and decreased by Ca^{2+} -stimulated kinase activity (Fig. 7E). Both the 61- and 69-kDa RGS6 isoforms are much larger than predicted from any transcripts identified in our original cloning effort (Chatterjee et al., 2003), suggesting they may represent novel RGS6 isoforms. In support of this hypothesis, northern blot analyses conducted in human brain and peripheral tissues indicate that there is at least one transcript predominantly expressed in the CNS that is larger than the other RGS6 transcripts (which correspond in size to the RGS6L and RGS6S splice forms; Snow et al., 1999).

Of the novel RGS6 protein bands described above, the 69-kDa RGS6B isoform is of particular interest. Importantly, we have shown that RGS6-specific inhibition of $G\alpha_{i/o}$ modulates several CNS disorders for which RGS6 may be a novel therapeutic target. Remarkably, RGS6^{-/-} mice have reduced anxiety/depression (Stewart et al., 2014), exhibit diminished alcohol seeking/reward (Stewart et al., 2015), and develop Parkinson's disease (Bifsha et al., 2014; Luo et al., 2019; Fig. 1). Re-examination of the Western blot data presented in these papers revealed that RGS6B is highly expressed in the brain regions affected by the CNS disorders described above, suggesting it plays a

critical role in CNS pathology. Therefore, future studies should focus on identifying the transcript encoding RGS6B so that its function may be further explored. There are several pieces of evidence derived from this study that may aid in transcript identification. First, RGS6B is recognized by the RGS6-L antibody (Fig. 4A, middle panel, green arrow), indicating the transcript will contain exons 1–6, which encode the long N-terminus. Second, RGS6B is also recognized by the RGS6-18 antibody (Fig. 4A, right panel, green arrow), indicating that the transcript includes exon 18. Finally, RGS6B is present in both mouse and human (Fig. 8B), indicating it is highly conserved. Therefore, the sequence of the identified transcript must be derived from highly conserved regions within the RGS6 gene.

Speculating on the possible effects of the rs2332700 SNP on RGS6 expression

In reflecting on the present data and the recent meta-analysis (Cross-Disorder Group of the Psychiatric Genomics Consortium, 2019) which linked a SNP (rs2332700) in RGS6 to autism spectrum disorder, bipolar disorder, major depression, and schizophrenia, it becomes intriguing to speculate on the SNP's functionality. The rs2332700 SNP maps to intron 1 of the RGS6 gene and is associated with a G > C switch. Interestingly, this SNP is only found in primates (Extended Data Fig. 5-2). While a functional role of this SNP has yet to be established, we hypothesize that it alters RGS6 expression. As RGS6L(+GGL) protein isoforms predominate (Fig. 5A, magenta arrow), we hypothesize that it is the physiological functions of these isoforms most highly impacted by the SNP. Interestingly, the RGS6L(+GGL) isoforms predominate not only in the CNS, but also in the periphery (Fig. 5), suggesting that the rs2332700 SNP may not only be linked to the psychological pathology of schizophrenia, autism spectrum disorder, bipolar disorder, and major depression, but also peripheral comorbidities associated with these diseases. In support of this hypothesis, we have demonstrated that global loss of RGS6 not only reduces CNS-associated alcohol seeking and reward behavior, in mice, but also protects against peripheral alcohol-mediated heart, liver, and gastrointestinal tract toxicity (Stewart et al., 2015).

Another intriguing piece of data from our current study is the discovery of a 69-kDa form of RGS6 that is brain-specific (RGS6B). Although the functional nature of RGS6B is unknown, numerous Western blot analyses conducted in this paper and others (Bifsha et al., 2014; Stewart et al., 2014, 2015; Luo et al., 2019) demonstrate that it is highly expressed in several brain regions associated with numerous psychiatric disorders including, but not limited to, alcohol use disorders, anxiety/depression, and Parkinson's disease. In addition, our current data suggest that RGS6B shares several structural similarities with the other predominant RGS6L(+GGL) isoforms (Fig. 4A). Therefore, it is intriguing to speculate that RGS6B expression may also be altered by the rs2332700 SNP. However, as RGS6B is not expressed in the periphery, we may surmise that alteration in its functional role would largely have psychological effects.

References

- Anderson GR, Semenov A, Song JH, Martemyanov KA (2007) The membrane anchor R7BP controls the proteolytic stability of the striatal specific RGS protein, RGS9-2. *J Biol Chem* 282:4772–4781.
- Anttila V, Bulik-Sullivan B, Finucane HK, Walters RK, Bras J, Duncan L, Escott-Price V, Falcone GJ, Gormley P, Malik R, Patsopoulos NA, Ripke S, Wei Z, Yu D, Lee PH, Turley P, Grenier-Boley B, Chouraki V, Kamatani Y, Berr C, et al. (2018) Analysis of shared heritability in common disorders of the brain. *Science* 360:eaap8757.
- Balasubramanian N, Levay K, Keren-Raifman T, Faurobert E, Slepak VZ (2001) Phosphorylation of the regulator of G protein signaling RGS9-1 by protein kinase A is a potential mechanism of light- and Ca²⁺-mediated regulation of G protein function in photoreceptors. *Biochemistry* 40:12619–12627.
- Benzing T, Brandes R, Sellin L, Schermer B, Lecker S, Walz G, Kim E (1999) Upregulation of RGS7 may contribute to tumor necrosis factor-induced changes in central nervous function. *Nat Med* 5:913–918.
- Benzing T, Köttgen M, Johnson M, Schermer B, Zentgraf H, Walz G, Kim E (2002) Interaction of 14-3-3 protein with regulator of G protein signaling 7 is dynamically regulated by tumor necrosis factor- α . *J Biol Chem* 277:32954–32962.
- Berman Dm, Wang Y, Liu Z, Dong Q, Burke La, Liotta La, Fisher R, Wu X (2004) A functional polymorphism in RGS6 modulates the risk of bladder cancer. *Cancer Res* 64:6820–6826.
- Bifsha P, Yang J, Fisher RA, Drouin J (2014) Rgs6 is required for adult maintenance of dopaminergic neurons in the ventral substantia nigra. *PLoS Genet* 10:e1004863.
- Chakravarti B, Yang J, Ahlers-Dannen KE, Luo Z, Flaherty HA, Meyerholz DK, Anderson ME, Fisher RA (2017) Essentiality of regulator of G protein signaling 6 and oxidized Ca(2+)/calmodulin-dependent protein kinase II in notch signaling and cardiovascular development. *J Am Heart Assoc* 6:e007038.
- Chatterjee TK, Liu Z, Fisher RA (2003) Human RGS6 gene structure, complex alternative splicing, and role of N terminus and G protein gamma-subunit-like (GGL) domain in subcellular localization of RGS6 splice variants. *J Biol Chem* 278:30261–30271.
- Cheever ML, Snyder JT, Gershburg S, Siderovski DP, Harden TK, Sondek J (2008) Crystal structure of the multifunctional Gbeta5-RGS9 complex. *Nat Struct Mol Biol* 15:155–162.
- Chen CK, Eversole-Cire P, Zhang H, Mancino V, Chen YJ, He W, Wensel TG, Simon MI (2003) Instability of GGL domain-containing RGS proteins in mice lacking the G protein beta-subunit Gbeta5. *Proc Natl Acad Sci USA* 100:6604–6609.
- Chen Fs, Shim H, Morhardt D, Dallman R, Krahn E, Mcwhinney L, Rao A, Gold SJ, Chen CK (2010) Functional redundancy of R7 RGS proteins in ON-bipolar cell dendrites. *Invest Ophthalmol Vis Sci* 51:686–693.
- Chen G, Zhang F, Xue W, Wu R, Xu H, Wang K, Zhu J (2017) An association study revealed substantial effects of dominance, epistasis and substance dependence co-morbidity on alcohol dependence symptom count. *Addict Biol* 22:1475–1485.
- Chograni M, Alkuraya FS, Maazoul F, Lariani I, Chaabouni-Bouhamed H (2014) RGS6: a novel gene associated with congenital cataract, mental retardation, and microcephaly in a Tunisian family. *Invest Ophthalmol Vis Sci* 56:1261–1266.
- Cross-Disorder Group of the Psychiatric Genomics Consortium (2013) Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. *Lancet* 381:1371–1379.
- Cross-Disorder Group of the Psychiatric Genomics Consortium (2019) Genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders. *Cell* 179:1469–1482.e11.
- Dai J, Gu J, Lu C, Lin J, Stewart D, Chang D, Roth JA, Wu X (2011) Genetic variations in the regulator of G-protein signaling genes are associated with survival in late-stage non-small cell lung cancer. *PLoS One* 6:e21120.
- Drenan RM, Doupnik CA, Boyle MP, Muglia LJ, Huettner JE, Linder ME, Blumer KJ (2005) Palmitoylation regulates plasma membrane-nuclear shuttling of R7BP, a novel membrane anchor for the RGS7 family. *J Cell Biol* 169:623–633.
- Gao Y, Shen M, Gonzalez JC, Dong Q, Kannan S, Hoang JT, Eisinger BE, Pandey J, Javadi S, Chang Q, Wang D, Overstreet-Wadiche L, Zhao X (2020) RGS6 mediates effects of voluntary running on adult hippocampal neurogenesis. *Cell Rep* 32:108114.
- Garrett S, Barton WA, Knights R, Jin P, Morgan DO, Fisher RP (2001) Reciprocal activation by cyclin-dependent kinases 2 and 7 is directed by substrate specificity determinants outside the T loop. *Mol Cell Biol* 21:88–99.
- Garzón J, Rodríguez-Muñoz M, López-Fando A, Sánchez-Blázquez P (2005) Activation of mu-opioid receptors transfers control of Galpha subunits to the regulator of G-protein signaling RGS9-2: role in receptor desensitization. *J Biol Chem* 280:8951–8960.
- GBD 2016 Disease and Injury Incidence and Prevalence Collaborators (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 390:1211–1259.
- Gold SJ, Ni YG, Dohlman HG, Nestler EJ (1997) Regulators of G-protein signaling (RGS) proteins: region-specific expression of nine subtypes in rat brain. *J Neurosci* 17:8024–8037.
- Gu Y, Rosenblatt J, Morgan DO (1992) Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. *EMBO J* 11:3995–4005.
- Hooks SB, Waldo GL, Corbitt J, Bodor ET, Krumins AM, Harden TK (2003) RGS6, RGS7, RGS9, and RGS11 stimulate GTPase activity of Gi family G-proteins with differential selectivity and maximal activity. *J Biol Chem* 278:10087–10093.
- Hu G, Wensel TG (2002) R9AP, a membrane anchor for the photoreceptor GTPase accelerating protein, RGS9-1. *Proc Natl Acad Sci USA* 99:9755–9760.
- Huang J, Yang J, Maity B, Mayuzumi D, Fisher RA (2011) Regulator of G protein signaling 6 mediates doxorubicin-induced ATM and p53 activation by a reactive oxygen species-dependent mechanism. *Cancer Res* 71:6310–6319.
- Huttlin EL, Jedrychowski MP, Elias JE, Goswami T, Rad R, Beausoleil SA, Villén J, Haas W, Sowa ME, Gygi SP (2010) A tissue-specific atlas of mouse protein phosphorylation and expression. *Cell* 143:1174–1189.
- Ibi M, Matsuno K, Matsumoto M, Sasaki M, Nakagawa T, Katsuyama M, Iwata K, Zhang J, Kaneko S, Yabe-Nishimura C (2011) Involvement of NOX1/NADPH oxidase in morphine-induced analgesia and tolerance. *J Neurosci* 31:18094–18103.
- Jiang N, Xue R, Bu F, Tong X, Qiang J, Liu R (2014) Decreased RGS6 expression is associated with poor prognosis in pancreatic cancer patients. *Int J Clin Exp Pathol* 7:4120–4127.
- Kessler RC, Wang PS (2008) The descriptive epidemiology of commonly occurring mental disorders in the United States. *Annu Rev Public Health* 29:115–129.
- Larminie C, Murdock P, Walhin JP, Duckworth M, Blumer KJ, Scheideler MA, Garnier M (2004) Selective expression of regulators of G-protein signaling (RGS) in the human central nervous system. *Brain Res Mol Brain Res* 122:24–34.
- Larochelle S, Pandur J, Fisher RP, Salz HK, Suter B (1998) Cdk7 is essential for mitosis and for in vivo Cdk-activating kinase activity. *Genes Dev* 12:370–381.
- Levay K, Cabrera JL, Satpaev DK, Slepak VZ (1999) G β 5 prevents the RGS7-G α o interaction through binding to a distinct G γ -like domain found in RGS7 and other RGS proteins. *Proc Natl Acad Sci USA* 96:2503–2507.
- Lishko PV, Martemyanov KA, Hopp JA, Arshavsky VY (2002) Specific binding of RGS9-Gbeta 5L to protein anchor in photoreceptor membranes greatly enhances its catalytic activity. *J Biol Chem* 277:24376–24381.
- Liu Z, Fisher RA (2004) RGS6 interacts with DMAP1 and DNMT1 and inhibits DMAP1 transcriptional repressor activity. *J Biol Chem* 279:14120–14128.

- Luo Y, Qin SL, Yu MH, Mu YF, Wang ZS, Zhong M (2015) Prognostic value of regulator of G-protein signaling 6 in colorectal cancer. *Biomed Pharmacother* 76:147–152.
- Luo Z, Ahlers-Dannen KE, Spicer MM, Yang J, Alberico S, Stevens HE, Narayanan NS, Fisher RA (2019) Age-dependent nigral dopaminergic neurodegeneration and α -synuclein accumulation in RGS6-deficient mice. *JCI Insight* 5:e126769.
- Maity B, Yang J, Huang J, Askeland RW, Bera S, Fisher RA (2011) Regulator of G protein signaling 6 (RGS6) induces apoptosis via a mitochondrial-dependent pathway not involving its GTPase-activating protein activity. *J Biol Chem* 286:1409–1419.
- Maity B, Stewart A, Yang J, Loo L, Sheff D, Shepherd AJ, Mohapatra DP, Fisher RA (2012) Regulator of G protein signaling 6 (RGS6) protein ensures coordination of motor movement by modulating GABAB receptor signaling. *J Biol Chem* 287:4972–4981.
- Maity B, Stewart A, O'Malley Y, Askeland RW, Sugg SL, Fisher RA (2013) Regulator of G protein signaling 6 is a novel suppressor of breast tumor initiation and progression. *Carcinogenesis* 34:1747–1755.
- Martemyanov KA, Lishko PV, Calero N, Keresztes G, Sokolov M, Strissel KJ, Leskov IB, Hopp JA, Kolesnikov AV, Chen CK, Lem J, Heller S, Burns ME, Arshavsky VY (2003) The DEP domain determines subcellular targeting of the GTPase activating protein RGS9 in vivo. *J Neurosci* 23:10175–10181.
- Martemyanov KA, Yoo PJ, Skiba NP, Arshavsky VY (2005) R7BP, a novel neuronal protein interacting with RGS proteins of the R7 family. *J Biol Chem* 280:5133–5136.
- Masuho I, Wakasugi-Masuho H, Posokhova EN, Patton JR, Martemyanov KA (2011) Type 5 G protein beta subunit (Gbeta5) controls the interaction of regulator of G protein signaling 9 (RGS9) with membrane anchors. *J Biol Chem* 286:21806–21813.
- Moon SW, Dinov ID, Kim J, Zamanyan A, Hobel S, Thompson PM, Toga AW (2015) Structural neuroimaging genetics interactions in Alzheimer's disease. *J Alzheimers Dis* 48:1051–1063.
- Patil DN, Rangarajan ES, Novick SJ, Pascal BD, Kojetin DJ, Griffin PR, Izard T, Martemyanov KA (2018) Structural organization of a major neuronal G protein regulator, the RGS7-G β 5-R7BP complex. *Elife* 7:e42150.
- Petyuk VA, Yu L, Olson HM, Yu F, Clair G, Qian WJ, Shulman JM, Bennett DA (2021) Proteomic profiling of the substantia nigra to identify determinants of Lewy body pathology and dopaminergic neuronal loss. *J Proteome Res* 20:2266–2282.
- Posokhova E, Wydeven N, Allen KL, Wickman K, Martemyanov KA (2010) RGS6/G β 5 complex accelerates IKACH gating kinetics in atrial myocytes and modulates parasympathetic regulation of heart rate. *Circ Res* 107:1350–1354.
- Psifogeorgou K, Papakosta P, Russo SJ, Neve RL, Kardassis D, Gold SJ, Zachariou V (2007) RGS9-2 is a negative modulator of mu-opioid receptor function. *J Neurochem* 103:617–625.
- Psifogeorgou K, Terzi D, Papachatzaki MM, Varidaki A, Ferguson D, Gold SJ, Zachariou V (2011) A unique role of RGS9-2 in the striatum as a positive or negative regulator of opiate analgesia. *J Neurosci* 31:5617–5624.
- Rorabaugh BR, Chakravarti B, Mabe NW, Seeley SL, Bui AD, Yang J, Watts SW, Neubig RR, Fisher RA (2017) Regulator of G protein signaling 6 protects the heart from ischemic injury. *J Pharmacol Exp Ther* 360:409–416.
- Ross EM, Wilkie TM (2000) GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins. *Annu Rev Biochem* 69:795–827.
- Safaei J, Manóuch J, Gupta A, Stacho L, Pelech S (2011) Prediction of 492 human protein kinase substrate specificities. *Proteome Sci* 9:S6.
- Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014) Biological insights from 108 schizophrenia-associated genetic loci. *Nature* 511:421–427.
- Sibbel SP, Talbert ME, Bowden DW, Haffner SM, Taylor KD, Chen YD, Wagenknecht LE, Langefeld CD, Norris JM (2011) RGS6 variants are associated with dietary fat intake in Hispanics: the IRAS Family Study. *Obesity (Silver Spring)* 19:1433–1438.
- Smoller JW, Andreassen OA, Edenberg HJ, Faraone SV, Glatt SJ, Kendler KS (2019) Psychiatric genetics and the structure of psychopathology. *Mol Psychiatry* 24:409–420.
- Snow BE, Betts L, Mangion J, Sondak J, Siderovski DP (1999) Fidelity of G protein beta-subunit association by the G protein gamma-subunit-like domains of RGS6, RGS7, and RGS11. *Proc Natl Acad Sci USA* 96:6489–6494.
- Sokal I, Hu G, Liang Y, Mao M, Wensel TG, Palczewski K (2003) Identification of protein kinase C isozymes responsible for the phosphorylation of photoreceptor-specific RGS9-1 at Ser475. *J Biol Chem* 278:8316–8325.
- Stewart A, Maity B, Wunsch AM, Meng F, Wu Q, Wemmie JA, Fisher RA (2014) Regulator of G-protein signaling 6 (RGS6) promotes anxiety and depression by attenuating serotonin-mediated activation of the 5-HT(1A) receptor-adenylyl cyclase axis. *FASEB J* 28:1735–1744.
- Stewart A, Maity B, Anderegg SP, Allamargot C, Yang J, Fisher RA (2015) Regulator of G protein signaling 6 is a critical mediator of both reward-related behavioral and pathological responses to alcohol. *Proc Natl Acad Sci USA* 112:E786–E795.
- Sullivan PF, Agrawal A, Bulik CM, Andreassen OA, Børglum AD, Breen G, Cichon S, Edenberg HJ, Faraone SV, Gelernter J, Mathews CA, Nievergelt CM, Smoller JW, O'Donovan MC; Psychiatric Genomics Consortium (2018) Psychiatric genomics: an update and an agenda. *Am J Psychiatry* 175:15–27.
- Trinidad JC, Barkan DT, Gullede BF, Thalhammer A, Sali A, Schoepfer R, Burlingame AL (2012) Global identification and characterization of both O-GlcNAcylation and phosphorylation at the murine synapse. *Mol Cell Proteomics* 11:215–229.
- Wydeven N, Posokhova E, Xia Z, Martemyanov KA, Wickman K (2014) RGS6, but not RGS4, is the dominant regulator of G protein signaling (RGS) modulator of the parasympathetic regulation of mouse heart rate. *J Biol Chem* 289:2440–2449.
- Xiang Z, Soto CS, Honig B (2002) Evaluating conformational free energies: the colony energy and its application to the problem of loop prediction. *Proc Natl Acad Sci USA* 99:7432–7437.
- Yang J, Huang J, Maity B, Gao Z, Lorca RA, Gudmundsson H, Li J, Stewart A, Swaminathan PD, Ibeawuchi SR, Shepherd A, Chen CK, Kutschke W, Mohler PJ, Mohapatra DP, Anderson ME, Fisher RA (2010) RGS6, a modulator of parasympathetic activation in heart. *Circ Res* 107:1345–1349.
- Yang J, Maity B, Huang J, Gao Z, Stewart A, Weiss RM, Anderson ME, Fisher RA (2013) G-protein inactivator RGS6 mediates myocardial cell apoptosis and cardiomyopathy caused by doxorubicin. *Cancer Res* 73:1662–1667.
- Yang J, Platt Lt, Maity B, Ahlers KE, Luo Z, Lin Z, Chakravarti B, Ibeawuchi SR, Askeland RW, Bondaruk J, Czerniak BA, Fisher RA (2016) RGS6 is an essential tumor suppressor that prevents bladder carcinogenesis by promoting p53 activation and DNMT1 downregulation. *Oncotarget* 7:69159–69172.
- Zhang S, Coso OA, Lee C, Gutkind JS, Simonds WF (1996) Selective activation of effector pathways by brain-specific G protein beta5. *J Biol Chem* 271:33575–33579.